

IN THE SPECIFICATION:

On page 1, please replace the paragraph beginning on line 4 with the following paragraph:

This application is a continuation of U.S. Patent Application Serial No. 09/456,357, filed December 8, 1999, which claims priority under 35 U.S.C. § 119(e) from U.S. Provisional Application Serial No. 60/134,416, filed May 17, 1999, entitled "Product for Production of Apoptosis-Inducing Proteins and Uses Therefor". ~~This application~~U.S. Patent Application Serial No. 09/456,357 is also a continuation-in-part of ~~copending~~ U.S. Patent Application Serial No. 09/087,195, filed May 29, 1998, now U.S. Patent No. 6,325,999 ~~entitled "Use of Fas Ligand to Suppress T-Lymphocyte-Mediated Immune Response"~~, which is a continuation of U.S. Patent Application Serial No. 08/378,507, now U.S. Patent No. 5,759,536, ~~issued June 2, 1998, entitled "Use of Fas Ligand to Suppress T-Lymphocyte-Mediated Immune Response"~~, which is a continuation-in-part of U.S. Patent Application Serial No. 08/250,478, filed May 27, 1994, ~~entitled "Use of Fas Ligand to Suppress T-Lymphocyte-Mediated Immune Response"~~, now abandoned. The entire disclosures of each of U.S. Patent Application Serial No. 09/456,357, U.S. Provisional Application Serial No. 60/134,416, U.S. Patent Application Serial No. 09/087,195, U.S. Patent No. 5,759,536 and U.S. Patent Application Serial No. 08/250,478 are incorporated herein by reference.